Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen
Lead Research Organisation:
King's College London
Department Name: Genetics and Molecular Medicine
Abstract
Cancer treatments which mobilise the patient's own immune system to fight cancerous cells (immunotherapy) are proving to be an exciting new approach in the fight against cancer. Antibodies are proteins that recognise alien entities in the body and trigger their destruction by immune cells. Antibodies recognising surface proteins (antigens) on cancer cells are now generated in the laboratory, designed to specifically seek out tumours displaying these surface antigens. To work, antibodies must also bind to immune cells, which in turn target those cancer cells. Antibodies come in five types, but only one, IgG, has been used in cancer therapy. Unfortunately, IgG binds relatively poorly to immune cells and works inefficiently in tissues, where tumours grow. Another antibody type, namely IgE, known as the key component of allergies, may be better suited to cancer therapy, because of its excellent binding to immune cells and ability to activate these cells in tissues. Our earlier work on designing IgE antibodies in relation to the therapy of ovarian cancer has already elicited encouraging results that engender optimism and we plan to test this antibody in patients soon.
We are now working to apply the same principles towards the treatment of the most lethal skin cancer, malignant melanoma. Melanoma cells are subject to immune scrutiny, that is they display on their surfaces antigens, the targets for an antibody. To investigate this, we produced CSPG4 IgE, an antibody specifically recognising melanoma cancer cells. When we tested this antibody in the laboratory, it was very effective in activating immune cells to destroy cancer. We now plan to complete these studies so that this therapy may benefit patients with malignant melanoma for whom few effective therapies are available.
We are now working to apply the same principles towards the treatment of the most lethal skin cancer, malignant melanoma. Melanoma cells are subject to immune scrutiny, that is they display on their surfaces antigens, the targets for an antibody. To investigate this, we produced CSPG4 IgE, an antibody specifically recognising melanoma cancer cells. When we tested this antibody in the laboratory, it was very effective in activating immune cells to destroy cancer. We now plan to complete these studies so that this therapy may benefit patients with malignant melanoma for whom few effective therapies are available.
Technical Summary
The clinical landscape for the lethal skin cancer, melanoma, is transformed by novel agents including an antibody targeting T-cell regulatory pathways, which, despite moderate clinical responses and high toxicities, demonstrates promise for antibody therapies. Yet, there are presently no antibodies directly targeting melanoma cells. This strategy entails an antibody targeting melanoma antigens that is engineered with Fc regions of the IgE antibody class. Attributes of IgE such as natural tissue immune activatory functions and high affinity for cognate Fc receptors on frequently tumour-resident effector cells can translate into superior protection against solid tumours compared to conventionally-used IgGs. These advantages are demonstrated by efficacy and safety in three in vivo tumour models and remarkable progress through process development of our successful first IgE antibody targeting Folate Receptor alpha-expressing cancers, now approaching first-in-man clinical trials supported by the CRUK New Agents Committee. We engineered IgE and IgG1 antibodies recognising CSPG4, a cell surface tumour antigen over-expressed by 80% of melanomas; CSPG4 participates in melanoma pathogenesis and progression through activation of key signalling pathways. CSPG4 IgE demonstrated superior efficacy in targeting melanoma and direct and cell-mediated tumour-killing activities, suggesting a multifactorial mode of action. Background IP is owned by KCL through a PCT application filed in 2011. Here, we will evaluate efficacy and safety of this agent through functional assays on patient and healthy volunteer blood and in disease-relevant models, some of which will also serve to support future evaluations in the pre-clinical development and clinical study stages. Study design is based on expertise with our lead antibody, to directly progress CSPG4 IgE to process development and clinical trials.
Planned Impact
Substantial knowledge on Th2 immunity in cancer and IgE functions in the context of cancer therapy is presently being acquired in conjunction with our parallel on-going research and development activities with our lead agent. These activities are fully supported from funds independent to this application and will contribute added-value to our existing activities. Collectively, our research and development activities and knowledge acquired as part of this proposed study towards the clinical application of the concept for a second target and in a different set of clinical indications are of paramount importance towards making this approach widely applicable for cancer therapy.
There are several options for the future progression of the programme, especially in relation to other cancer types known to express CSPG4. This would include expansion into larger indications such as breast cancer, including breast carcinomas termed "triple-negative." This latter programme, as part of our newly funded Breakthrough Breast Cancer Unit at King's College London/Guy's Hospital (5-year Unit headed by Prof. Andrew Tutt; co-PIs: Karagiannis, Nestle, Ng) will commence with in vitro and in vivo models of breast cancer. Application as a therapy for breast cancer and specifically for triple-negative breast carcinomas is expected to report results in parallel with data acquired as part of this proposed study and will provide added value to this study.
This study also stands to make a substantial impact in the wider field of immune and antibody therapeutics. Our research on Th2 immunity, IgE and cancer is receiving increasing attention from the academic, medical and biotechnology communities. We have been approached by three biotechnology companies (Novartis, Biotechnol, UCB) who have shown strong interest specifically in relation to IgE immunotherapy, for example toward a collaborative effort to develop IgE antibody fragments with multiple specificities including CSPG4
If successful this proposed study will: a) point to strategies by which Th2 immune responses could be harnessed to target tumours; b) provide a new therapeutic avenue to potentially benefit the majority of the 112,000 in the UK living with malignant melanoma; c) pave the way towards the development of a new class of therapeutic antibody agents with improved immune activatory functions which could be redirected against cancers of different origins.
If unsuccessful, this study will be informative in informing the design of novel immune activatory strategies, especially those aimed at overcoming tumour-induced immune escape mechanisms and those aimed at re-educating inflammatory cells to attack rather than promote tumour growth.
There are several options for the future progression of the programme, especially in relation to other cancer types known to express CSPG4. This would include expansion into larger indications such as breast cancer, including breast carcinomas termed "triple-negative." This latter programme, as part of our newly funded Breakthrough Breast Cancer Unit at King's College London/Guy's Hospital (5-year Unit headed by Prof. Andrew Tutt; co-PIs: Karagiannis, Nestle, Ng) will commence with in vitro and in vivo models of breast cancer. Application as a therapy for breast cancer and specifically for triple-negative breast carcinomas is expected to report results in parallel with data acquired as part of this proposed study and will provide added value to this study.
This study also stands to make a substantial impact in the wider field of immune and antibody therapeutics. Our research on Th2 immunity, IgE and cancer is receiving increasing attention from the academic, medical and biotechnology communities. We have been approached by three biotechnology companies (Novartis, Biotechnol, UCB) who have shown strong interest specifically in relation to IgE immunotherapy, for example toward a collaborative effort to develop IgE antibody fragments with multiple specificities including CSPG4
If successful this proposed study will: a) point to strategies by which Th2 immune responses could be harnessed to target tumours; b) provide a new therapeutic avenue to potentially benefit the majority of the 112,000 in the UK living with malignant melanoma; c) pave the way towards the development of a new class of therapeutic antibody agents with improved immune activatory functions which could be redirected against cancers of different origins.
If unsuccessful, this study will be informative in informing the design of novel immune activatory strategies, especially those aimed at overcoming tumour-induced immune escape mechanisms and those aimed at re-educating inflammatory cells to attack rather than promote tumour growth.
Publications
Egbuniwe I
(2016)
355 A human in vivo model of a cutaneous memory B cell immune response to skin antigen challenge
in Journal of Investigative Dermatology
Saul L
(2016)
483 Alternative activation of cutaneous B cells and IgG antibody subclass polarisation in melanoma
in Journal of Investigative Dermatology
Imberti C.
(2016)
68Ga in vivo chelation with tris(hydroxypyridinone) ligands
in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Marlow R
(2015)
Abstract 1459: Patient-derived xenograft models of breast cancer with human immune components
in Cancer Research
Karagiannis P
(2016)
Abstract A009: IgG4: a new tool to predict the risk of disease progression in melanoma
in Cancer Immunology Research
Fittall M
(2016)
Abstract A089: The circulating memory B cell compartment of breast cancer patients is depleted in comparison with healthy volunteers
in Cancer Immunology Research
Fittall M
(2016)
Abstract A090: Exploring folate receptor a immunotherapy of breast carcinomas: Human monocytic cell-mediated killing triggered by IgG1 and IgE antibodies
in Cancer Immunology Research
Abdul-Jawad S
(2021)
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.
in Cancer cell
Jensen-Jarolim E
(2017)
AllergoOncology - the impact of allergy in oncology: EAACI position paper.
in Allergy
Josephs D. H.
(2018)
AllergoOncology: An immunologically relevant rodent model demonstrates safety of a tumour-specific IgE therapy
in ALLERGY
Fazekas-Singer J.
(2018)
AllergoOncology: Anti-EGFR IgE triggers potent tumor cell killing by mast cells and monocytes
in ALLERGY
Pellizzari G.
(2016)
AllergoOncology: characterization of a monoclonal IgE antibody (SF-25 IgE) as a novel immunotherapy candidate for solid tumours
in ALLERGY
Ilieva K.
(2016)
AllergoOncology: development of IgE antibodies for breast cancer immunotherapy
in ALLERGY
Ilieva KM
(2019)
AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.
in Allergy
Cheung A.
(2017)
Allergooncology: folate receptor alpha as a therapeutic target in breast carcinomas using recombinant antibodies
in ALLERGY
Fazekas-Singer J
(2018)
AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor.
in The Journal of allergy and clinical immunology
Singer J
(2019)
AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice.
in The World Allergy Organization journal
Jensen-Jarolim E
(2017)
AllergoOncology: IgE- and IgG 4 -mediated immune mechanisms linking allergy with cancer and their translational implications
in Journal of Allergy and Clinical Immunology
Untersmayr E
(2019)
AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper.
in Allergy
Description | A clinically integrated translational science programme to progress positive biomarker and therapeutics development for forms of breast cancer currently defined as Triple Negative Breakthrough Research Unit, KCL, Q3 |
Amount | £3,899,998 (GBP) |
Funding ID | Breakthrough Research Unit, KCL, Q3 and Q4 |
Organisation | Breast Cancer Now |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2018 |
End | 10/2025 |
Description | Antibody Discovery |
Amount | £380,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 02/2023 |
Description | Antibody discovery |
Amount | £24,000,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start | 03/2007 |
End | 03/2017 |
Description | Antibody engineering to identify optimal expression systems and glycoforms of IgE class antibodies for cancer therapy |
Amount | £120,000 (GBP) |
Funding ID | MRC iCASE Award |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2023 |
Description | Antibody engineering to identify optimal expression systems and glycoforms of IgE class antibodies for cancer therapy |
Amount | £130,000 (GBP) |
Funding ID | 2468071 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2019 |
End | 12/2023 |
Description | Antibody-drug conjugates (ADCs) for the treatment of solid tumours |
Amount | £130,000 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2024 |
Description | Antibody-drug conjugates (ADCs) for the treatment of solid tumours |
Amount | £149,549 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2024 |
Description | BBSRC |
Amount | £70,794 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2017 |
End | 09/2017 |
Description | Biobanking and clinical assay development |
Amount | £98,000 (GBP) |
Organisation | Guy’s & St Thomas’ Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2019 |
End | 09/2025 |
Description | Boehringer Ingelheim Fonds travel grant |
Amount | € 2,830 (EUR) |
Funding ID | Ms Judit Fazekas, Medical University of Vienna, travelling fellowship to King's College London |
Organisation | Boehringer Ingelheim |
Department | Boehringer Ingelheim Fonds |
Sector | Charity/Non Profit |
Country | Germany |
Start | 03/2017 |
End | 05/2017 |
Description | Breakthrough Research Unit, KCL, Q2 |
Amount | £3,500,000 (GBP) |
Funding ID | KCL-Q2 |
Organisation | Breast Cancer Now |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2013 |
End | 10/2018 |
Description | Clinical Lectureship for Dr Debra Josephs, Academic Oncology (50% research); Co-supervisors: Spicer (clinical), Karagiannis (research) |
Amount | £150,000 (GBP) |
Organisation | Health Education England |
Department | Health Education South London |
Sector | Public |
Country | United Kingdom |
Start | 03/2013 |
End | 12/2017 |
Description | Crosstalk Between Tumour and Draining Lymph Nodes and its Impact on Triple-Negative Breast Cancer |
Amount | £644,533 (GBP) |
Funding ID | MR/W025221/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2022 |
End | 11/2025 |
Description | Delineating B cell Responses and Signalling Pathways in Patients with Solid Tumours |
Amount | £120,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2023 |
Description | Delineating B cell Responses and Signalling Pathways in Patients with Solid Tumours |
Amount | £100,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2023 |
Description | Development of a specific cancer immunotherapeutic that targets an innate immune checkpoint |
Amount | £64,281 (GBP) |
Funding ID | N/A |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2018 |
End | 03/2019 |
Description | EAACI Exchange Research Fellowship |
Amount | € 5,000 (EUR) |
Funding ID | For Ms Judit Fazekas from the Medical University of Vienna, Project title: Cloning And Characterization Of Anti-HER-2 Immunoglobulins Of Different Ig-Classes In Regard Of ADCC And ADCP |
Organisation | European Academy of Allergy and Clinical Immunology (EAACI) |
Sector | Charity/Non Profit |
Country | Switzerland |
Start | 03/2016 |
End | 06/2016 |
Description | European Academy of Allergy and Clinical Immunology (EAACI) Task Force Status Award |
Amount | € 49,500 (EUR) |
Funding ID | AllergoOncology Task Force, Award for Task Force Activities part of the European Academy of Allergy and Clinical Immunology (EAACI) |
Organisation | European Academy of Allergy and Clinical Immunology (EAACI) |
Sector | Charity/Non Profit |
Country | Switzerland |
Start | 01/2015 |
End | 12/2023 |
Description | Evaluation of Novel Antibody-Drug Conjugates (ADCs) for the Treatment of Solid Tumours |
Amount | £130,000 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2025 |
Description | Generation of Antibody Drug Conjugate (ADC) technologies for site specific conjugation to toxins |
Amount | £130,000 (GBP) |
Funding ID | 2395805 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2024 |
Description | High-Performance Glycoengineering of IgE Antibodies |
Amount | £100,000 (GBP) |
Funding ID | 2577529 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2017 |
End | 04/2023 |
Description | IgE Class Antibody Engagement and Activation of Human Monocyte and Macrophage Subsets for Cancer Immunotherapy |
Amount | £130,000 (GBP) |
Funding ID | 2059719 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2018 |
End | 03/2023 |
Description | IgE Class Antibody Engagement and Activation of Human Monocyte and Macrophage Subsets for Cancer Immunotherapy |
Amount | £120,000 (GBP) |
Organisation | MRC Doctoral Training Program |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2023 |
Description | IgE antibodies in cancer |
Amount | £696,741 (GBP) |
Organisation | IGEM Therapeutics Ltd |
Sector | Private |
Country | United Kingdom |
Start | 02/2018 |
End | 01/2020 |
Description | IgE antibodies in cancer |
Amount | £2,454,224 (GBP) |
Organisation | IGEM Therapeutics Ltd |
Sector | Private |
Country | United Kingdom |
Start | 02/2018 |
End | 12/2024 |
Description | Immune effector cell-mediated functions of PIPE-cloned Bet v 1 antibodies engineered with Fc regions of different isotypes c |
Amount | € 5,750 (EUR) |
Funding ID | EFIS-Immunology Letters (IL) Short-Term Fellowship Verena Koehler |
Organisation | European Federation of Immunological Societies (EFIS) |
Sector | Charity/Non Profit |
Country | Germany |
Start | 09/2019 |
End | 01/2020 |
Description | Immune landscape of the premetastatic lymph node in lymph node positive invasive breast cancer patients |
Amount | £130,000 (GBP) |
Funding ID | 2072211 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2018 |
End | 12/2022 |
Description | Impact of B cell and antibody responses in patients with melanoma |
Amount | £140,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2022 |
End | 09/2026 |
Description | Mechanisms of action and therapeutic potential of monoclonal antibodies targeting cancer |
Amount | £120,000 (GBP) |
Funding ID | King's Health Schools Studentship |
Organisation | King’s Health Partners |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2014 |
End | 09/2018 |
Description | Modulation of B lymphocytes and antibody immune responses to solid tumours |
Amount | £150,000 (GBP) |
Funding ID | S_3605 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2017 |
End | 10/2021 |
Description | Modulation of B lymphocytes and antibody responses to breast cancer tumours |
Amount | £149,913 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2017 |
End | 12/2021 |
Description | NIHR PhD studentship scheme |
Amount | £100,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start | 09/2017 |
End | 09/2021 |
Description | Phase I study of MOv18, a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours: pre-clinical and clinical evaluations. |
Amount | £301,082 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2015 |
End | 06/2022 |
Description | Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen |
Amount | £314,000 (GBP) |
Organisation | IGEM Therapeutics Ltd |
Sector | Private |
Country | United Kingdom |
Start | 03/2017 |
End | 12/2021 |
Description | Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen |
Amount | £977,992 (GBP) |
Funding ID | MR/L023091/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2015 |
End | 05/2019 |
Description | Preclinical validation of a novel cancer immunotherapeutic |
Amount | £786,656 (GBP) |
Funding ID | 51746 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 08/2020 |
End | 12/2022 |
Description | The humoral immune response in patients with melanoma undergoing checkpoint inhibitor therapy |
Amount | £263,702 (GBP) |
Funding ID | S_3957 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2020 |
End | 05/2023 |
Description | The humoral immune response in patients with melanoma undergoing checkpoint inhibitor therapy |
Amount | £264,000 (GBP) |
Funding ID | Clinical Fellowship |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 01/2023 |
Description | The impact of antibody isotype on patient monocyte and macrophage functions and activation states to manipulate anti-tumour responses in melanoma |
Amount | £290,084 (GBP) |
Funding ID | MR/V049445/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2024 |
Description | Collaboration on development of a specific cancer immunotherapeutic that targets an innate immune checkpoint |
Organisation | King's College London |
Department | Division of Cancer Studies |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Cloning, engineering of checkpoint immunotherapy agent. |
Collaborator Contribution | Design and testing of cancer immunotherapy. |
Impact | Multidisciplinary collaboration with academic group for the development of immunotherapeutic agent. |
Start Year | 2018 |
Description | Partnership to conduct a Phase I study of MOv18, a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours: pre-clinical and clinical evaluations. |
Organisation | Cancer Research UK |
Department | Cancer Research UK Drug Development Office |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Development of IgE therapeutic agent and clinical trial assays. |
Collaborator Contribution | Sponsoring clinical trial. |
Impact | Approval of first-in-class clinical trial, active trial. |
Start Year | 2015 |
Description | Partnership to define and design altered IgE glycoforms |
Organisation | Ludger Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | Our laboratory is leading novel work to examine the role of glycans for IgE activity, and to exploit this knowledge for the development of altered IgE glycoforms. Bringing together expertise in IgE pharmacology (Karagiannis), chemical inhibitors of glycan biosynthesis (Wagner) and high-performance glycoanalytics (Ludger Ltd), we will provide proof-of-concept for a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins. |
Collaborator Contribution | Ludger Ltd provide high-performance glycoanalytics to establish a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins. |
Impact | Work has begun using high-performance glycoanalytics to establish a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins.therapy supported by two funding awards: BBSRC Industrial CASE Award, Antibody glyco-engineering, £100,000, Oct 2017-Sept 2021; Wagner G, Karagiannis S; BBSRC NIBB IBCarb Network, Proof of Concept grant, Defining and designing optimized IgE glycoforms, £70,794, Jan-Sept 2017; (PIs: Wagner G, Karagiannis S) has yielded a publication: Crescioli S et al. published in 2018 (J Allergy Clin Immunol. 2018 Jan 19. doi: 10.1016/j.jaci.2017.12.986). https://www.ludger.com/news/ |
Start Year | 2016 |
Description | Partnership to develop novel Antibody-drug Conjugate agents |
Organisation | Femtogenix Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | Partnership with Femtogenix Ltd, UK, to develop novel Antibody-drug Conjugate agents for the treatment of solid tumours. |
Collaborator Contribution | Provision of toxic payload drugs and expertise in the ADC field. |
Impact | Successful NIHR funded PhD Studentship award. £120,000 in October 2016. |
Start Year | 2016 |
Title | ANTIBODY |
Description | In one aspect, the present invention relates to an immunoglobulin E (IgE) for use in repolarizing macrophages from a first phenotype to an anti-tumor phenotype in the treatment of cancer in a subject; wherein the first phenotype comprises a quiescent (M0) macrophage phenotype or an anti-inflammatory (M2a) macrophage phenotype; and the anti-tumor phenotype comprises a newly polarized macrophage phenotype characterized by expression of the following cytokines and chemokines: tumor necrosis factor alpha (TNFa); interferon-gamma (IFN?); interleukin-1beta (IL-1ß); interleukin-6 (IL-6); Regulated on Activation, Normal T cell Expressed and Secreted (RANTES or CCL5); and/or interleukin-10 (IL-10). |
IP Reference | WO2020148425 |
Protection | Patent application published |
Year Protection Granted | 2020 |
Licensed | Commercial In Confidence |
Impact | Supports the ability of IgE immunotherapies to re-polarise the tumour microenvironment, this may result in patient selection or stratification and contributes to translation of IgE therapies, pioneered in my group. |
Title | COMPOSITION COMPRISING AN IGE ANTIBODY |
Description | In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody. |
IP Reference | WO2021214329 |
Protection | Patent / Patent application |
Year Protection Granted | 2021 |
Licensed | Commercial In Confidence |
Impact | The invention also relates to methods of treating diseases such as cancer using such IgE antibodies and dosage regimens. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021214329 |
Title | IGE ANTI -HMW-MAA ANTIBODY |
Description | In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fcepsilon receptor. |
IP Reference | WO2013050725 |
Protection | Patent granted |
Year Protection Granted | 2013 |
Licensed | Yes |
Impact | Development of a novel antibody class recognising a melanoma-associated antigen. One reagent is progressing in pre-clinical functional studies. |
Title | IGE ANTI-HMW-MAA Antibody |
Description | In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an FCC receptor. |
IP Reference | US2018094074 |
Protection | Patent application published |
Year Protection Granted | 2018 |
Licensed | Yes |
Impact | Licenced to commercial partner. |
Title | MOv18 IgE: Phase I study of a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours |
Description | This clinical study relates to MOv18 IgE, a chimeric anti-folate receptor alpha (FRa) monoclonal IgE antibody. Extensive pre-clinical research studies have led to this first-in-human (FIH), first-in-class, proof-of-concept trial of MOv18 IgE, in patients with advanced cancer to investigate the potential of the IgE class of antibodies in solid tumour indications. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2022 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
UKCRN/ISCTN Identifier | http://docplayer.net/31096743-London-cancer-alliance-clinical-trials-directory-phase-i-studies.html |
Impact | This trial is first time a therapeutic antibody of the IgE class has been administered to man. The data generated from the trial will provide essential information to aid the development of this particular agent and other future IgE therapeutics, including IgE analogues of existing therapeutic IgG monoclonal antibodies, as well as new agents. |
URL | https://clinicaltrials.gov/ct2/show/NCT02546921 |
Company Name | IGEM Therapeutics/ Epsilogen Ltd. |
Description | IGEM Therapeutics now named Epsilogen Ltd. is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. |
Year Established | 2017 |
Impact | Epsilogen Ltd. is developing a novel antibody platform technology based on engineering of the epsilon constant region. |
Website | https://epsilogen.com/ |
Description | AIRC Foundation for Cancer Research (AIRC) My First AIRC Grant (MFAG) Review Panel, 2022 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | AIRC Foundation for Cancer Research (AIRC) My First AIRC Grant (MFAG) Review Panel Member, 2022 |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.direzionescientifica.airc.it/funding-for-research/individual-grants/my-first-airc-grant/ |
Description | Academy of Finland, Research Council of Biosciences, Health and the Environment Evaluation Panel (Life06_22 / Immunology) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Academy of Finland, Research Council of Biosciences, Health and the Environment Evaluation Panel (Life06_22 / Immunology), Panel member |
Year(s) Of Engagement Activity | 2021,2022,2023 |
Description | Advsory Committee of EuroMabNet |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Karagiannis chaired a session and was speaker at the 11th EuroMabNet Meeting, 17th September 2021; and at the 12th EuroMabNet Meeting, 22-24th September, 2022. https://www.euromabnet.com/meeting/11th-meeting-online.php; https://www.euromabnet.com/meeting/12th-meeting-hamburg.php |
Year(s) Of Engagement Activity | 2022,2023 |
URL | https://www.euromabnet.com/ |
Description | AllergoOncology Working Group |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Co-founder, and Secretary of AllergoOncology, Task Force 2015-2020 and Working Group 2021 onwards. International consortium on collaborative research into Th2 & IgE immunity in cancer; actively supported by the European Academy for Allergy and Clinical Immunology, EAACI |
Year(s) Of Engagement Activity | 2015,2016,2017,2018,2019,2020,2021,2022,2023 |
URL | https://eaaci.org/working-group/allergooncology/ |
Description | Article in Nursing in Practice; Title: New tools to treat malignant melanoma. |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Lead author of article in nursing magazine. Karagiannis SN*, Lacy KE. New tools to treat malignant melanoma. Nursing In Practice. http://www.nursinginpractice.com/article/new-tools-treat-malignant-melanoma, 20 May, 2015 |
Year(s) Of Engagement Activity | 2012,2015 |
URL | http://www.nursinginpractice.com/article/new-tools-treat-malignant-melanoma |
Description | Breast Cancer Now Sponsored Worshop - The British Science Festival, Coventry & Warwickshire |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | The British Science Festival, Coventry & Warwickshire, 10-13 September 2019; Panel member and speaker at the Breast Cancer Now-sponsored patient engagement event OC23; Title: Breast cancer breakthroughs, Tuesday 10 September, University of Warwick, Zeeman, MS 01, Coventry |
Year(s) Of Engagement Activity | 2019 |
Description | Breast Cancer Now and ASDA senior leadership visit at King's College London, Guy's Cancer Centre, Innovation Hub, 28th April 2022 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | Breast Cancer Now and ASDA senior leadership visit at King's College London, Guy's Cancer Centre, Innovation Hub, 28th April 2022 |
Year(s) Of Engagement Activity | 2022 |
Description | Breast Cancer Now social media live event, Guest speaker: 24th May 2021, 12th April 2022 , Breast Cancer Now Facebook Live |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | BREAST CANCER NOW social media live event, Guest speaker: o 24th May 2021, Breast Cancer Now Facebook Live "Research in Triple Negative Breast Cancer" o 12th April 2022 Breast Cancer Now Facebook Live "Not one type of breast cancer". |
Year(s) Of Engagement Activity | 2021,2022 |
Description | CRUK Commercial Partnership, CRUK entrepreneurial initiative with Converge, Activate Challenge Wales and Northern Ireland, Keynote speaker 23rd February 2022 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | CRUK Commercial Partnership, CRUK entrepreneurial initiative with Converge, Activate Challenge Wales and Northern Ireland, Keynote speaker 23rd February 2022 |
Year(s) Of Engagement Activity | 2022 |
Description | Cancer Research UK Cancer Innovation Event, The Crick Science Entrepreneur Network at The Francis Crick Institute - Invited Panel Member 14th February 2023 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Invited to join Panel for Cancer Research UK Cancer Innovation Event, The Crick Science Entrepreneur Network at The Francis Crick Institute, 14th February 2023 |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.linkedin.com/feed/update/urn:li:activity:7032126397779234816/ |
Description | Cancer Research UK Discovery Research Committee, Immunology Expert Review Panel, 2021, 2022; Clinical Research Committee (CRC), 2023 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Cancer Research UK Discovery Research Committee, Immunology Expert Review Panel, autumn 2021 |
Year(s) Of Engagement Activity | 2021,2022,2023 |
Description | Cancer Research UK communications and philanthropy team; Breakfast Club Invited speaker, Clifford Chance, London |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Supporters |
Results and Impact | Cancer Research UK communications and philanthropy team; Breakfast Club Invited speaker, Clifford Chance, Canary Wharf, London, February 2020 |
Year(s) Of Engagement Activity | 2020 |
Description | Clinical Trials Day held at Guy's Hospital in May 2015 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Our team provided stall cover and a poster on IgE antibodies in oncology for the Clinical Trials Day at Guy's Hospital. |
Year(s) Of Engagement Activity | 2014,2015 |
Description | Danish Cancer Society: Scientific committee - Biology & Clinic (KBVU-BK) 2022-24 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Danish Cancer Society: Scientific committee member - Biology & Clinic (KBVU-BK), 2022-2024 |
Year(s) Of Engagement Activity | 2022,2023 |
URL | https://www.cancer.dk/forskning/stoette-til-forskning/funding/experimental/ |
Description | Discussion with 6th Form students at St Columba's College, St Alban's |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | A discussion on studying Science and Medicine subjects at University. Discussion on what a career in Science and Research entails. |
Year(s) Of Engagement Activity | 2020 |
Description | Grant review Panel of the South-Eastern Norway Regional Health Authority, Oslo, Norway (Helse Sør-Øst RHF) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Member of Grant Review Panel of the South-Eastern Norway Regional Health Authority, Oslo, Norway (Helse Sør-Øst RHF) |
Year(s) Of Engagement Activity | 2019,2020,2021,2022 |
Description | Guest Speaker, "From Bench to Market" training workshop, Skillfluence |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | Guest Speaker, "From Bench to Market" training workshop, Skillfluence (http://www.skillfluence.co.uk/), Health Sciences Doctoral Training Centre, |
Year(s) Of Engagement Activity | 2018 |
Description | Guest Speaker, Antibodies to activate our immune system against cancer |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Access Aspiration, the Mayors Fund for London, guest speaker at virtual event, November 2020, attended by 100 students from all backgrounds, https://twitter.com/mayorsfund/status/1331987467059257349 |
Year(s) Of Engagement Activity | 2020 |
URL | https://twitter.com/mayorsfund/status/1331987467059257349 |
Description | Guest Speaker, Antibodies to activate our immune system against cancer |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Other audiences |
Results and Impact | Visit and talk to GCSE and 6th Form Students at St Andrew The Apostle School |
Year(s) Of Engagement Activity | 2021 |
Description | Guy's and St Thomas's NHS Trust Members' Health Seminar, Dermatology, 7th September 2016 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Invited to speak and engage with public at Guy's and St Thomas's NHS Trust Members' Health Seminar, Dermatology, 7th September 2016, Moles and Melanoma, Antibodies for cancer therapy; http://www.guysandstthomas.nhs.uk/news-and-events/past-events.aspx |
Year(s) Of Engagement Activity | 2016 |
URL | http://www.guysandstthomas.nhs.uk/news-and-events/past-events.aspx |
Description | Interview on immuno-oncology research and translating first-in-class antibody to clinic, CRUK Autumn 2018 Progress Update |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | Interview on immuno-oncology research and translating first-in-class antibody to clinic, CRUK Autumn 2018 Progress Update, https://philanthropyandpartnerships.cancerresearchuk.org/ProgressUpdateAutumn2018/ |
Year(s) Of Engagement Activity | 2018 |
URL | https://philanthropyandpartnerships.cancerresearchuk.org/ProgressUpdateAutumn2018/ |
Description | Invited speaker at Melanoma Discussion Group For Patients, Family and Friends, St John's Institute of Dermatology, Guy's and St Thomas' Hospitals NHS Trust |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Invited to this patient support group to discuss research on melanoma and design of antibodies including those of the IgE class. |
Year(s) Of Engagement Activity | 2013,2014,2015 |
Description | Invited speaker at St Andrew the Apostle Greek Orthodox School, North London: two invited talks to Lower and Upper 6th Form students about careers in science and on antibodies as immunotherapies to activate the immune system against cancer, 24th June 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Invited to St Andrew the Apostle Greek Orthodox School, North London. Delivered two invited talks to Lower and Upper 6th Form students about careers in science and on antibodies as immunotherapies to activate the immune system against cancer, 24th June 2021 |
Year(s) Of Engagement Activity | 2021 |
Description | Invited speaker at the Cancer Research UK's Translate Your Research with the Centre for Drug Development (CDD) Seminar, King's College London |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Industry/Business |
Results and Impact | Invited speaker at the Cancer Research UK's Translate Your Research with the Centre for Drug Development (CDD) Seminar, Innovation Hub, Guy's Cancer Centre, Guy's Hospital, 8th October 2019 |
Year(s) Of Engagement Activity | 2019 |
Description | Invited speaker to MSc in Entrepreneurship and Innovation, King's Business School |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | MSc in Entrepreneurship and Innovation, King's Business School, Strand Campus; Guest Speaker; Anna Perman, February 2019; February 2020 |
Year(s) Of Engagement Activity | 2019,2020 |
Description | Invited speaker: The Gordon Research Conference: Antibody Biology and Engineering (GRC): Invited Speaker (IgE Immunotherapy: Targeting Cancer by Re-Educating Macrophages) Antibody Biology and Engineering (GRC), Connecting B Cell Biology with Antibody Structure, Function and Applications, 13-18 March 2022, Ventura Beach California, United States. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The Gordon Research Conference: Antibody Biology and Engineering (GRC): Invited Speaker (IgE Immunotherapy: Targeting Cancer by Re-Educating Macrophages) Antibody Biology and Engineering (GRC), Connecting B Cell Biology with Antibody Structure, Function and Applications, 13-18 March 2022, Ventura Beach California, United States. Chairs: Jeanette Leusen and Laura M. Walker, Vice Chairs: Pierre Bruhns and Lynn Macdonald. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.grc.org/antibody-biology-and-engineering-conference/2022/ |
Description | Laboratory visit by patients and families from St John's Institute of Dermatology (skin cancer support group) on the 21st April 2016, St John's Institute of Dermatology, 9th floor, Guy's Tower Wing. |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | The Karagiannis group hosted an afternoon meeting and visit to the laboratories by patients and families from St John's Institute of Dermatology (skin cancer support group) on the 21st April 2016, St John's Institute of Dermatology, 9th floor, Guy's Tower Wing. Co-hosts: Consultant Dermatologist, Consultant Medical Oncologist, Clinical Psychologist, Skin Cancer, St John's Institute of Dermatology. |
Year(s) Of Engagement Activity | 2016 |
Description | Oncostars initiative event, PanaceaStars and Cancer Research UK |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Other audiences |
Results and Impact | Oncostars initiative event, PanaceaStars and Cancer Research UK, 'Innovating cancer research: trends, challenges and future perspectives' November 2019, Francis Crick Institute, London; |
Year(s) Of Engagement Activity | 2019 |
Description | Radcliffe Department of Medicine Careers Day, St Anne's College, University of Oxford |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker at a Careers Day event, at St Anne's College, University of Oxford in April 2015 |
Year(s) Of Engagement Activity | 2015 |
URL | http://www.cardiov.ox.ac.uk/rdm-careers-day-2 |
Description | Scientific Evaluation Committee (SEC), The ERA-NET TRANSCAN-3: The European Commission under H2020, Joint Transnational Call for proposals (JTC 2021) (JTC 2022) (2021-23) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Member of the Scientific Evaluation Committee (SEC), The ERA-NET TRANSCAN-3: The European Commission under H2020, Joint Transnational Call for proposals (JTC 2021) (JTC 2022) (2021-23) |
Year(s) Of Engagement Activity | 2021,2022,2023 |
URL | https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl |
Description | SouthEast London Cancer Consumer Panel for Research (SELCRP) member |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Southeast London Cancer Consumer Panel for Research (SELCRP) researcher member, providing scientific input for peer review activities. Continuous service since 2013 |
Year(s) Of Engagement Activity | 2013,2014,2015,2016,2017,2018,2019,2020,2021,2022,2023 |
URL | https://www.guysandstthomasbrc.nihr.ac.uk/patients-public/how-can-i-become-involved/cancer-research/ |
Description | Speaker and Host, King's Stars 2019 Outreach Programme |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | King's Stars 2019 Outreach Programme, July 2019, talk, discussion and hosted laboratory visits for sixth-form students from diverse backgrounds. |
Year(s) Of Engagement Activity | 2018,2019 |
Description | Talk at business breakfast event with Cancer Research UK Philanthropy Team |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Supporters |
Results and Impact | Karagiannis has been working with the CRUK Philanthropy Team and the Catalyst Club. She gave a talk on translational research at a Business Breakfast held in London in February 2018. |
Year(s) Of Engagement Activity | 2018 |
Description | Talk on Present and future monoclonal antibody therapies for breast cancer to the Breast Cancer Now Clinical and Helpline, Breast Cancer Now, London, 9th November 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | Invited talk on Present and future monoclonal antibody therapies for breast cancer to the Breast Cancer Now Clinical and Helpline bi annual update day, Breast Cancer Now, London, 9th November 2019. |
Year(s) Of Engagement Activity | 2019 |
Description | Talk on immune responses to melanoma and immunotherapy approaches at the UK National DermSoc Day, 14th March 2018, British Association of Dermatologists, London UK |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker at the UK National DermSoc Day, British Association of Dermatologists, 14th March 2018, London UK. Talk title: B cells and antibody responses in patients with melanoma in the immunotherapy era: new insights. This invited talk was designed to educate and inspire young clinical dermatology medical trainees (medical students and junior doctors) to appreciate translational research that has and is expected to lead to important breakthroughs in the therapy of melanoma skin cancer. The talk led to discussions with clinical trainees and young doctors. |
Year(s) Of Engagement Activity | 2018 |
URL | http://www.bad.org.uk/healthcare-professionals/education/medical-students/dermsoc |
Description | The Greek Scientists Society 3rd Symposium "Leveraging the soft power of the global Hellenic Community: Towards the Greek & Cypriot next-gen innovation ecosystems 5.0", Panel 4: Why Greeks are successful in the Life Sciences sector? How can we incorporate our distinctive talent to the dawn of the Greek Biopharma innovation? Invited Panel Speaker |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | The Greek Scientists Society 3rd Symposium "Leveraging the soft power of the global Hellenic Community: Towards the Greek & Cypriot next-gen innovation ecosystems 5.0", Panel 4: Why Greeks are successful in the Life Sciences sector? How can we incorporate our distinctive talent to the dawn of the Greek Biopharma innovation? 27th March 2022, Invited Panel Speaker |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.youtube.com/watch?v=5A6K4uCv04E&t=18s |
Description | The South East London Cancer Consumer Panel for Research SELCRP |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | I serve as a panel member (researcher expert/representative) supporting the panel's work providing research and ethics feedback to researchers. |
Year(s) Of Engagement Activity | 2013,2014,2015,2016,2017,2018,2019,2020,2021 |
URL | http://www.guysandstthomasbrc.nihr.ac.uk/PatientsPublic/Getinvolved/Haveyoursay/Cancer-research/Canc... |
Description | Visit by Breast Cancer Now and the Sarah Greene Tribute Fund members and supporters: King's College London/Guy's Hospital laboratory site visit, 31st Jan 2017 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Supporters |
Results and Impact | Our team co-hosted an afternoon visit by Breast Cancer Now and the Sarah Greene Tribute Fund members and supporters: King's College London/Guy's Hospital laboratory site visit, 31st Jan 2017. This event included presentations, question and answer sessions and visits to our laboratory facilities with presentations from laboratory group members. |
Year(s) Of Engagement Activity | 2017 |
Description | Work experience student placements |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | The Karagiannis laboratory hosted 2 6th form students as work experience in June 2017. |
Year(s) Of Engagement Activity | 2017 |